Page 3 - Binding Affinity News Today

Researchers generated six human monoclonal antibodies that prevented infection.

In a recent article published in the journal Science Translational Medicine, researchers showed that a novel, lab-engineered monoclonal antibody (mAb), adintrevimab conferred up to 50% protection against symptomatic coronavirus disease 2019 (COVID-19). Furthermore, it demonstrated this exceptional efficacy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–naïve individuals even at titers as low as 1:30.

Researchers in the US examined the neutralization evasion and receptor affinity properties of SARS-CoV-2 Omicron BA.2.75 sub-variants.

In a recent study published in the journal mBio, researchers in the United States evaluated rat exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City (NYC).

In a recent study posted to the bioRxiv* preprint server, researchers engineered epitope scaffolds (ESs) of conserved regions of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

Researchers assessed the impact of a single-dose dendritic cell vaccine candidate on immune responses against SARS-CoV-2.

Researchers assessed the impact of SARS-CoV-2 spike NTD incorporation into the RBD protein vaccine.

A study published in PLOS PATHOGENS describes the prevalence and functions of mutations in neuraminidase enzyme of avian H5N1 influenza viruses that are preferentially selected in human H5N1 influenza viruses.

A recent study describes the binding affinity and docking sites of several natural compounds, as well as their inhibitory activity against 3CLpro.

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.